SUDA LTD

ACN 090 987 250

ASX Release

SUDA LTD UPDATES ON PROGRESS OF ARTIMIST™ ANTI-MALARIAL SPRAY

- **Preparing documentation for marketing applications in major territories**
- **Initiated dialogue with global organisations associated with treatment of malaria**
- **Establishing a Scientific Advisory Board to advise on expanding the product's potential**
- **Retaining an internationally renowned advisory company for pharmaceutical licensing and trade sales**

PERTH, AUSTRALIA - 28 October 2013: Suda Ltd (ASX: SUD) today provides an update on developments and plans for the commercialisation of its lead product candidate, ArTiMist™, for the treatment of severe malaria in children. The Company is making progress on several fronts.

ArTiMist™ is the world's first anti-malarial sub-lingual (under the tongue) spray for malaria. The active ingredient, artemether, is widely used and is currently administered either by infusion or in a tablet form. Suda reported compelling Phase III final results demonstrating the safety and efficacy of ArTiMist™ versus intravenous quinine in August 2013.

The team is working hard to finalise the Common Technical Document (CTD) for ArTiMist™. The CTD is a comprehensive report used as part of applications for registration of medicines in all major territories of the world. The CTD includes not only the clinical study reports, but also details on manufacturing, pharmacology and toxicology.

In September 2013, the Company had an encouraging dialogue with the global partnership, Medicines for Malaria Venture (MMV). MMV has offered to assist Suda in raising the profile of ArTiMist™ with global funds and groups such as the World Health Organisation.

As a next step, Suda is establishing a Scientific Advisory Board (SAB) of key opinion leaders in the field of malaria. The SAB will provide invaluable advice as the Company expands the potential of the product from a first-line treatment of severe malaria to include use in the pre-referral setting (ie: when a child first develops a fever or has other danger

signs associated with severe malaria). In addition, the involvement of highly respected academics and clinicians will further raise the profile of ArtiMist™ in the global malaria community. The members of the SAB will be announced in due course.

The management team continues to identify suitable pharmaceutical companies that have an interest in acquiring or licensing the Company's anti-malarial assets. To assist with the process, Suda is in the process of retaining an international advisory company, renowned for sourcing and negotiating pharmaceutical licensing deals and trade sales. The strategy will include an extensive outreach initiative to the pharmaceutical industry over the next six months.

"Our objective is to realise the value from our ArTiMist™ asset. We have a robust strategy to achieve this objective and we are making excellent progress," said Stephen Carter, Suda Ltd's Executive Chairman and CEO. "The kind of partner we are looking for is a major pharmaceutical company with an existing franchise in malaria and other tropical diseases. By engaging key opinion leaders for our Scientific Advisory Board and retaining a leading advisory firm in life science transactions, we will be well positioned to secure the best possible deal for ArTiMist™."

Further information:
STEPHEN CARTER
EXECUTIVE CHAIRMAN
SUDA LTD
Tel: +61 8 6142 5555
sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

Suda Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. Suda's most advanced product is a novel sub-lingual treatment, ArTiMist™, for severe malaria in children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other development stage products include orals sprays for the treatment of migraine headache, erectile dysfunction and chemotherapy-induced nausea and vomiting.